



Immunotherapy in Triple Negative Breast Cancer

Guest Editor:

Dr. Yuanliang Yan

Department of Pharmacy,
Xiangya Hospital, Central South
University, Changsha, China

Deadline for manuscript
submissions:

closed (28 February 2023)

Message from the Guest Editor

Dear Colleagues,

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, leading to poor prognosis and therapeutic response. Today, immunotherapy, such as immune checkpoint inhibitors (ICIs) and cell vaccine, is increasingly being used to treat TNBC patients. The biological function of immunotherapy in TNBC has resulted in durable clinical response and improved clinical outcomes. These findings have helped us to understand the importance of immune-response-based strategies for TNBC treatment. The aim of this Special Issue in the *Journal of Personalized Medicine (JPM)* is to highlight the current state of the report and showcase some of the latest findings in the field of immune-response-based strategies for TNBC patients. Manuscripts based on basic science, clinical, and population-based approaches are especially welcome.

Dr. Yuanliang Yan

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)